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ARHGEF9 disease
Phenotype clarification and genotype-phenotype correlation
ABSTRACT
Objective: We aimed to generate a review and description of the phenotypic and genotypic spec-
tra of ARHGEF9 mutations.
Methods: Patients with mutations or chromosomal disruptions affecting ARHGEF9 were identi-
fied through our clinics and review of the literature. Detailed medical history and examination
findings were obtained via a standardized questionnaire, or if this was not possible by reviewing
the published phenotypic features.
Results: A total of 18 patients (including 5 females) were identified. Six had de novo, 5 had mater-
nally inherited mutations, and 7 had chromosomal disruptions. All females had strongly skewed
X-inactivation in favor of the abnormal X-chromosome. Symptoms presented in early childhood
with delayed motor development alone or in combination with seizures. Intellectual disability
was severe in most and moderate in patients with milder mutations. Males with severe intellectual
disability had severe, often intractable, epilepsy and exhibited a particular facial dysmorphism.
Patients with mutations in exon 9 affecting the protein’s PH domain did not develop epilepsy.
Conclusions: ARHGEF9 encodes a crucial neuronal synaptic protein; loss of function of which
results in severe intellectual disability, epilepsy, and a particular facial dysmorphism. Loss of only
the protein’s PH domain function is associated with the absence of epilepsy. Neurol Genet 2017;3:
e148; doi: 10.1212/NXG.0000000000000148
GLOSSARY
AED 5 antiepileptic drug; Cb 5 collybistin; NGS 5 next-generation sequencing; XLID 5 X-linked intellectual disability.
X-chromosomal mutations are a common cause of intellectual disability (X-linked intellec-
tual disability [XLID]) in males accounting for 10%–12% of ID.1,2 XLID is highly hetero-
geneous and is usually divided into syndromic and nonsyndromic forms, depending on the
association with particular clinical findings.1,2 Epileptic seizures accompany XLID in almost
half the disorders, in some beginning in infancy prior to the developmental delay being
evident. Recent next-generation sequencing (NGS) approaches have expedited the identifi-
cation of XLID genes, including those associated with epilepsy,1–3 many of which encode
proteins involved in synaptic function.4 ARHGEF9 is one such gene,5–9 encoding collybistin
(Cb), a brain-specific guanine nucleotide exchange factor with an essential role in
inhibitory synaptic transmission.5 Cb interacts with the inhibitory receptor–anchoring
protein gephyrin and is required for the formation of gephyrin and gephyrin-dependent
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GABAA clusters in the postsynaptic mem-
brane (figure 1).5,8,10 Cb knockout mice
exhibit increased anxiety, impaired spatial
learning, and convulsions.10,11
Over 10 patients with ARHGEF9 muta-
tions have been reported,5–9,12–15 indicating
that this will likely be one of the more com-
mon XLIDs. Descriptions of the published
cases vary from scant (in large NGS projects)
to case reports with substantial detail. In the
present study, we combine detailed descrip-
tions of the phenotypes of 18 patients with
ARFGH9 mutations. In 4 cases, adequate
detail was present at first published descrip-
tion. In 6 cases, we went back to the patients
mentioned in tables of NGS results and
worked with their physicians to obtain clin-
ical details. The remaining are new unpub-
lished patients.
METHODS Two brothers (patients P10 and P11) with ID and
epilepsy and unremarkable MRIs were tested by clinical whole-
exome sequencing and found to have mutations in the ARH-
GEF9 gene. Further 16 patients (including 5 females) with
mutations or chromosomal disruptions affecting ARHGEF9 were
identified through a literature review and by contacting genetic
centers in North America, Asia, and Europe.
Standard protocol approvals, registrations, and patient
consents. A detailed developmental epilepsy and general medical
history together with examination findings were obtained for each
patient via a standardized questionnaire filled by their treating
physician, or if this was not possible by a review of the described
phenotypic features in publications. No samples were obtained
from patients for research purposes. Written consent was ob-
tained from patients’ parents for the publication of recognizable
photographs.
X-chromosome inactivation analysis. In the unpublished
cases (patients P1, P3, and P4) X-chromosome inactivation anal-
ysis was performed with the human androgen receptor assay:
amplification of the CAG repeat in exon 1 of the androgen recep-
tor gene was performed by PCR with fluorescence-tagged pri-
mers. Subsequently, digestion with the methylation-sensitive
enzyme HpaII was performed, and fragments were analyzed with
an automated capillary sequencer (ABI 3100; Applied Bio-
systems, Foster City, CA). Genescan and Genotyper Software
(Applied Biosystems) were used to determine fragment sizes and
intensities, and the degree of X-inactivation was calculated.
RESULTS Genetic findings. Tables 1 and 2 summa-
rize the genetic findings of the 18 patients. Eleven had
hemizygous ARHGEF9 mutations, including prema-
ture stop codon, splicing, and point mutations. Six
were de novo mutations; the 2 above brothers (P10
and 11) and patients P8, P15, and P18 showed
a maternal inheritance, the latter with 3 affected
brothers with a similar phenotype. Seven had chro-
mosomal disruptions. The 11 mutations were in
exons 8 (3), 9 (2), 1 (1), 3 (1), 4 (1), 5 (1), and 7
(1), and in intron 9 (1) (exon numbering based on the
longest ARHGEF9 transcript NM_015185.2). The
patients with chromosomal disruptions had deletions
(4), translocations (2), and a paracentric inversion (1).
The 5 female patients all showed skewed X-inactivation
of the normal chromosome.
Clinical features. Tables 1 and 2 summarize the clinical
features of the 18 patients.
Demographics. Current age or age at last examination
ranged from 4 to 57 years. Presenting symptoms: onset
Figure 1 Interaction of collybistin in the postsynaptic membrane
Schematic representation of the interactions of collybistin in the formation of gephyrin and gephyrin-dependent GABAA
clusters in the postsynaptic membrane.
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of symptoms occurred at a mean age of 15 months
(median 9 months, range 1 day–7 years). Present-
ing symptoms varied from seizures (5), develop-
mental delay in combination with seizures (4),
and developmental delay/intellectual disability
alone (6). One patient presented with hyperek-
plexia and seizures shortly after birth and 1 patient
with hyperarousal and developmental delay (with
no seizures).
Intellectual disability. The majority of patients (13)
showed delayed early developmental milestones. All
patients had ID ranging from mild (1) to moderate
(7) to severe (10). Of the 10 patients with severe
ID, 7 were nonverbal.
Neuropsychiatric features. Autistic features were re-
ported in 4 patients. Five patients had hyperactivity.
Dysmorphic features. Photographs for review of dys-
morphic features were available for 9 of the 18 pa-
tients. Eight patients showed mild facial dysmorphic
features. Out of this group, it appears that the male
patients who are most severely affected with the over-
all neurologic syndrome (i.e., most severe ID and seiz-
ures) show more distinctive and consistent facial
features, including enlarged, fleshy earlobes, a sunken
Table 1 Genetic findings and phenotypic features of patients with ARHGEF9 mutations or disruptions (females)
Genetic findings and
clinical features
(reference) P1 P28 P3 P4 P59
Chromosomal disruption Balanced
translocation (46,XX, t
(X;20)(q12;P13))
Balanced translocation (46,
X, t(X;18)(q11.1;q11.21))
27 kb Xq11.1 deletion:
arrXq11.1
(62,838,630–
62,865,334)
7.5 kb Xq11.1 deletion:
arrXq11.1 (62,854,862–
62,862,403)x1
Paracentric inversion (46,
X,inv(X)(q11.1q27.3))
Inheritance De novo De novo De novo De novo De novo
X-inactivation (testing) Skewed 100 (RT-PCR
with ARHGEF9
primers vs controls)
Skewed 100 (RT-PCR with
ARHGEF9 primers vs
controls)
Skewed 95:5 (RT-PCR
with ARHGEF9 primers
vs controls)
Skewed 90:10 (Mercier) Skewed 100 (replication
studies on
phytohemagglutinin-
stimulated T lymphocytes
after BrdU incorporation)
Functional study N/A Loss of gephyrin 1 GABAAR
clusters
N/A N/A N/A
Current age/age of
examination (AE)
10 15 (AE) 9 4 25
Presenting age and
symptoms
10 mo; SZ, DD 7 mo; DD 12 mo; DD 31 mo; SZ, DD 18 mo; HA, DD
Dysmorphic features CD Facial Facial Facial Facial
Somatic parameter,
percentile
C N/A; H ,3; W 3 C ,3; H ,3; W ,3 C 50; H 3; W 90 C 90; H 90; W 90 C N/A; H 65; W 60
Developmental
milestones, mo
S: 12; W: 16 S: 21 S: 15; W: 22 S: 11; W: 30; Wo: 42 W: 13; Wo: 20
Intellectual disability
(IQ testing)
Severe Severe Moderate Moderate Moderate (48)
Autistic features Yes NR No No No
Hyperactivity Yes Yes Yes No No
Hyperekplexia No No No No No
Hyperarousal No No No No Yes
MRI Normal Normal Normal N/A UF
Epilepsy Yes Yes No Yes No
Seizure types GTC GTC — F, GTC —
Seizure onset 10 mo 7 y — 31 mo —
EEG findings Gen. SW Slow BG — Normal —
AEDs VPA, PHT, PGB VPA, CLB — None —
Response to AED ,50% red NR — Seizure free —
Other features Nonverbal,
hyperpigmentation
Nonverbal (auto-)
aggressive behavior, sleep
problems, OSA, insensitivity
to thermal pain
Hypotonia, pes
adductus, sleep
problems
PE, enhanced tendon
reflexes, mild joint
hypermobility
Sensory hyperarousal
Abbreviations: AED 5 antiepileptic drug; BG 5 background; BrdU 5 bromodeoxyuridine; C 5 head circumference; CD 5 clinodactyly; CLB 5 clobazam;
DD 5 developmental delay; GTC 5 generalized tonic-clonic seizures; H 5 height; HA 5 hyperammonemia; N/A 5 not applicable; NR 5 not reported; OSA 5
obstructive sleep apnea; PE 5 pectus excavatum; PGB 5 pregabalin; PHT 5 phenytoin; RT 5 real time; S 5 sitting; SW 5 spike and wave; SZ 5 seizures;
UF 5 unspecific findings; VPA 5 valproate; W 5 body weight; W 5 independent walking.
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Table 2 Genetic findings and phenotypic features of patients with ARHGEF9 mutations or disruptions (males)
Genetic findings and clinical
features (reference) P67 P76 P86 P95 P10 P11 P12
Chromosomal disruption/
NM number
1.29 Mb Xq11.11
deletion: arrXq11.1
(61,848,414–
63,138,698) [Hg18]x0
737 kb Xq11.11
deletion: arrXq11.1
(62,321,746–
63,058,548) x.dn
NM_001173479 NM_015185.2 NM_015185.2 NM_015185.2 NM_015185.2
Complementary DNA level N/A N/A c.4C.T c.164G.A c.950C.G c.950C.G c.530T.C
Protein level N/A N/A p.Q2a p.G55A p.S317W p.S317W p.L177P
Genomic DNA N/A N/A 63005022G.A 62944437C.T 62885872G.C 62885872G.C 62917036A.G
Exon N/A N/A 1 3 8 8 5
Domain N/A N/A None SH3 None None DH
Functional study N/A N/A N/A Loss of gephyrin 1
GABAAR clusters
N/A N/A N/A
Inheritance De novo De novo Maternally De novo Maternally Maternally De novo
Current age/age of
examination (AE)
11 5 (AE) 5 (AE) D (4) 23 31 4
Presenting age and
symptoms
5 mo; SZ 9 mo; DD 6 mo; DD Birth; HE; SZ 13 mo; SZ 30 mo; SZ 4 mo; SZ
Dysmorphic features Facial No No NR Facial Facial No
Somatic parameter,
percentile
C 97; H 97; W 97 C 90–97; H 75–90; W
.97
C 75–90; H 50–75; W
10–25
NR C 50; H 25; W 10–25 C P50; H 97; W .97 C 25–50; H 90–97; W
50–75
Developmental
milestones, mo
S: 12; W: 23 S: 12; W: no S: 12; W: 24 NR S: 12; W: 18 S: 6; W: 15 W: 20
Intellectual disability (IQ
testing)
Severe Severe Severe Severe Severe Severe Severe
Autistic features No NR NR NR Yes No Yes
Hyperactivity Yes NR NR NR No No No
HE No NR NR Yes No No No
Hyperarousal No NR NR NR No No No
MRI Normal HFL PMG BA UF Normal Normal
Epilepsy Yes Yes Yes Yes Yes Yes Yes
Seizure types FD, GTC FD GTC T (startle) GTC F, FD, GTC FC, FD, GTC
Seizure onset 5 mo 24 mo 20 mo Birth 13 mo 30 mo 4 mo
EEG findings Normal Bilateral temporal SW CSWS NR Gen. 2 Hz SW, slow BG Gen. 2 Hz SW, slow BG Slow BG, 4 Hz rhythm
AEDs CBZ, PB, TPM, LEV,
OXC
VPA Multiple AEDs PB, LTG VPA, CBZ, CLB CBZ, CLB VPA, LEV, LTG
Continued
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Table 2 Continued
Genetic findings and clinical
features (reference) P67 P76 P86 P95 P10 P11 P12
Response to AED 50% red Seizure free Refractory Refractory 50% red 50% red 50% red
Other features Nonverbal, PE,
aggressive behavior
Nonverbal, trigono-
cephalic head
Nonverbal, ataxic gait HE — Nonverbal Nonverbal, hypospadia
nevus flammeus, sleep
problems
Genetic findings and clinical
features (reference) P13 P1415 P1512,13 P1614 P1714 P18
Chromosomal disruption/NM
number
NM_015185.2 NM_015185.2 NM_015185.2 NM_015185.2 NM_015185.2 NM_015185.2
Complementary DNA level c.311G.A c.869G.A c.1012C.T c.1198G.A c.130012T.C c.1067G.A
Protein level p.R104Q p.R290H p.R338W p.E400K p. ? Exon skipping p.R356Q
Genomic DNA 62926208C.T 62893973C.T 62885810G.A 62875476C.T 62875372A.G 62875607C.T
Exon 4 7 8 9 Intron 9 9
Domain DH DH PH PH None PH
Functional study N/A Reduced PI3P-binding 1
loss of gephyrin clusters
Reduced PI3P-binding 1
loss of gephyrin clusters
N/A N/A N/A
Inheritance De novo De novo Maternally De novo De novo Maternally
Current age/age of
examination (AE)
15 57 26 (AE) 2 (AE) 3 (AE) 28
Presenting age and symptoms 12 mo; SZ, DD 6 mo; SZ, DD N/A 6 mo; DD 2 mo; SZ 7 y; ID
Dysmorphic features No No Facial Facial Facial, CD No
Somatic parameter,
percentile
C 60; H ,3; W ,3 N/A C 90; H 70 C 10–25; H 25–50; W
10–25
C 97; H 50; W N/A C 97; H 75; W 75
Developmental milestones,
mo
S: 18; W: no N/A NR S: 12; W: 29 S:12; W: no S: 6; W: 12; Wo: 12
Intellectual disability (IQ
testing)
Severe Moderate (40–50) Moderate (43) Moderate Moderate Mild (50–70)
Autistic features Yes No No NR NR No
Hyperactivity Yes No NR NR NR No
HE No No NR NR NR No
Hyperarousal No No NR NR NR No
MRI UF HS N/A Normal MD N/A
Epilepsy Yes Yes Yes No No No
Seizure types F, GTC, M, T FD, GTC NR — — —
Seizure onset 12 mo 6 mo NR — — —
EEG findings MISF, 4 Hz rhythm, slow BG Temporal SW NR — — —
Continued
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appearance of the middle face (midface hypoplasia) in
combination with a protruding of the jaw (progna-
thism) (figure 2). Two patients showed 5-digit
clinodactyly.
Neuroimaging findings. MRI data were available in
15 patients. Findings were none (7), hippocampal
sclerosis (1), hypoplastic frontal lobe (1), brain atro-
phy (1), polymicrogyria (1), delayed myelination
(1), or nonspecific (T2 hyperintensities, accentuated
perivascular spaces) (3).
Seizure/epilepsy details. Thirteen patients had epi-
lepsy with onset at a mean age of 20 months (median
12 months, range 1 week–7 years). Seizure types were
variable, including generalized tonic-clonic (9), focal
dyscognitive (5), focal (4), myoclonic (1), and tonic
(2) seizures. EEG findings were available for 11 of the
13 patients and showed generalized (3), bilateral (1),
multifocal (1), and focal (1) epileptiform discharges
and were normal in 2 patients. One patient with
polymicrogyria showed continuous spike-and-wave
discharges in slow-wave sleep. Two patients had on-
ly moderate background slowing.
Epilepsy treatment. Four patients had medically
refractory epilepsy, 4 showed 50% seizure reduction
with antiepileptic drugs (AEDs), 1 showed seizure
reduction of less than 50%, and 2 became completely
seizure free without further AED treatment. AEDs
consisted mainly of combination therapy (10); only
1 patient was on monotherapy (1).
Additional features included sleep disorder (4),
ataxic gait (1), aggressive behavior (2), fetal finger
and toe pads (2), pigmentation abnormalities (2),
pectus excavatum (2), hyperreflexia (1), tachypnea
(1), macro-orchidism (1), and insensitivity to thermal
pain (1).
DISCUSSION We describe and review the pheno-
types of 18 patients with ARHGEF9 mutations and
chromosomal disruptions. Symptoms usually present
in early childhood with delayed motor development
alone or in combination with seizures. ID later on is
usually moderate to severe with the majority of severe
cases being nonverbal.
Epilepsy is common (13/18), starting usually at an
early age (median 12 months). Seizure semiology is
variable with a majority of patients showing general-
ized tonic-clonic seizures and many showing multiple
seizure types. Most of the epilepsies were difficult to
treat with 10 patients on combination AED therapy.
Facial dysmorphism, in particular, enlarged ear-
lobes, midface hypoplasia, and prognathism appear
to be a constant feature of the neurologically severely
affected male patients.
The overall picture, therefore, is one of a moder-
ate-to-severe XLID (with severe cases nonverbal),
moderate-to-severe epilepsy (with severe cases poorly
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responsive or intractable to AEDs), and a facial dys-
morphism in the severe cases.
Mothers of the various male patients in our study
do not have XLID, indicating that random skewing of
X-inactivation protects female carriers of ARHGEF9
mutations. We did, however, find 5 female patients.
X-inactivation studies in all 5 showed skewing in
favor of the abnormal X-chromosome (table 1), ren-
dering them equivalent to male counterparts with
hemizygous mutations. The female phenotype would
invariably be affected by remaining expression from
the normal allele in cells in which it is active, and by
differences in the extent of X-inactivation skewing in
the brain compared to leucocytes.
Close analysis of males in the genotype and phe-
notype tables (1 and 2, respectively) suggests a tenta-
tive genotype—epilepsy phenotype correlation
related to the region of the protein affected by the
mutation. To clarify this, we briefly review some
aspects of Cb structure and function. Inhibitory
neurotransmitter receptor channels (GABAA and
glycine) imbedded in the postsynaptic membrane
are anchored and clustered therein by a submem-
brane lattice composed of the gephyrin protein. The
gephyrin lattice itself binds the plasma membrane
via intermediary proteins critical among which is
Cb. Cb binds gephyrin through its DH domain
and attaches to the membrane through both its ter-
mini as follows: the N-terminal SH3 domain binds
the membrane-integral neuroligin-2 protein, and
the C-terminal PH domain binds the phosphoino-
sitol 3-phosphate (PI3P) constituent of the plasma
membrane (figure 1).5,8,10 In male patients P6 and
P7, the entire ARHGEF9 gene is deleted, and in
patient P8, there is a premature stop in the second
codon (table 1). These 3 patients therefore lack Cb
altogether, and their phenotypes would be represen-
tative of the complete loss of Cb function. Table 2
shows that all 3 have severe ID and epilepsy. Pa-
tients 9 through 15 have various missense muta-
tions affecting different regions of the protein, but
not the C-terminal PI3P-interacting PH domain.
All have epilepsy. Where functional experiments
were performed (patients 9, 14, and 15), it was
shown that the mutations result in loss of gephyrin
clusters.5,12,16 The 3 remaining patients (16 through
18) all have mutations that affect the PH domain.
None of these patients have epilepsy (and all have
mild-to-moderate ID). Therefore, tentatively, mu-
tations affecting only the PI3P-interacting C-termi-
nus of the protein are not associated with epilepsy.
Future functional experiments for these and subse-
quent PH domain mutations may uncover differ-
ences from the effects of the epileptogenic
mutations and a possible understanding of epilepto-
genesis in this disease.
An additional important observation gleaned from
our summary tables is comparing male patients P8
and P9 (table 2). Patient P8 has a stop mutation,
p.Q2*, in the very first exon, and his symptom con-
stellation is very severe and similar to patients P6 and
P7 in whom the entire gene is deleted. This first exon
is coding, and therefore mutation p.Q2* truncating,
in a shorter transcript (NM_001173479) that skips
over the next 2 exons utilized by the longest transcript
(NM_015185.2) of the gene. The shorter transcript,
NM_001173479, was confirmed to be highly ex-
pressed in both the developing and adult human
brain and may be the dominant transcript.6 Patient
P9 is the very first ARHGEF9 patient described, and
a striking feature of his presentation was hyperekplex-
ia. His mutation is in exon 2, of the longer transcript,
which is not utilized by the shorter transcript. Hyper-
ekplexia is not found in any of the patients described
Figure 2 Facial dysmorphism of 2 severely affected male patients
Patients P6 (A) and P11 (B) from tables 1 and 2. Note enlarged fleshy earlobes, midface
hypoplasia, and prognathism.
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after that first patient (tables 1 and 2), which suggests
that this symptom may result from a particular func-
tion of the slightly longer protein encoded by the
longer transcript.
As in so many other neurogenetic disorders, our
review reveals that the ARHGEF9 disease is not uni-
form and varies with the gene mutation and likely
other genetic and extragenetic factors. Therefore,
the diagnostic approach in candidate patients still
requires chromosomal microarray testing as the
first-line genetic testing because of the substantial
diagnostic yield and low relative cost, followed by
a gene panel or whole-exome sequencing approach
as second tier.
There is, however, a core phenotype of moderate-
to-severe ID and epilepsy with a facial dysmorphism
(large earlobes, midface hypoplasia, and prognathism)
in patients with complete loss of the gene’s function.
This phenotype is moderated with lesser mutations—
less severe intellectual disability and seizures, and
absence of facial dysmorphism. As mentioned, mu-
tations affecting the last exon alone appear to be
nonepiletogenic.
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